Cortechs.ai | Revolutionizing Imaging Diagnostics with Cortechs.ai CEO, Kyle Frye

Revolutionizing Imaging Diagnostics with Cortechs.ai CEO, Kyle Frye

Cortechs.ai CEO Kyle Frye Featured on SCALE Community Healthcare Technology & Innovation Podcast

We’re excited to share that Kyle Frye, CEO of Cortechs.ai, recently sat down with the SCALE Community Healthcare Technology & Innovation Podcast for an insightful conversation about the future of medical technology. As a market leader and innovator in AI-powered solutions for neurology, radiology, and oncology, Cortechs.ai is transforming healthcare through advanced imaging technologies.

In this episode, Kyle dives into how Cortechs.ai leverages clinical data and machine learning to empower physicians with more accurate and timely diagnostic insights. Listeners will hear about the company’s pioneering advancements, such as their state-of-the-art imaging solutions that improve patient outcomes and streamline clinical workflows.

Key topics discussed include:

  • The impact of AI-powered quantitative MRI in transforming radiology
  • Innovative solutions for neuroimaging and prostate cancer diagnosis
  • How data-driven insights are revolutionizing the decision-making process for physicians
  • The company’s vision for continued innovation in healthcare technology

Don’t miss this engaging conversation with Kyle as he shares how Cortechs.ai is shaping the future of medical imaging and empowering healthcare professionals worldwide.

You can listen to the podcast on:

Tune in to discover how Cortechs.ai is advancing clinical care through cutting-edge technology!

More Resources

03/13/2026

Cortechs Cares: Community Impact and Volunteer Efforts in 2025

Cortechs Cares highlights how our team gave back in 2025 through community volunteer efforts, including an Alzheimer’s Walk and holiday toy drive.

03/11/2026

OnQ™ Prostate: Bringing Quantitative MRI to Prostate Imaging

Advancing prostate MRI with quantitative diffusion biomarkers. OnQ™ Prostate brings objective RSI-based insights to support data-driven cancer evaluation.

03/04/2026

Cortechs.ai and Siemens Healthineers Partner to Expand Global Access to NeuroQuant® Technologies

NeuroQuant® Lesion Surveillance will be integrated into the Siemens Healthineers Digital Marketplace to advance quantitative brain imaging worldwide.

02/25/2026

Cortechs.ai Announces MFDS (KFDA) Approval of Global-Leading NeuroQuant® V5 Platform in South Korea

MFDS approves NeuroQuant® V5 in South Korea, expanding AI-driven volumetric neuroimaging and clinical decision support.

02/24/2026

Financial Conflict Of Interest Policy Applicable To NIH Awards

02/20/2026

NeuroQuant® PET: FDA 510(k)-Pending Advancement in Molecular Dementia Imaging

FDA 510(k)-Pending NeuroQuant® PET delivers automated, standardized quantification for amyloid, tau, and FDG imaging in dementia care.
Scroll to Top